Applications published 31 October 2007

Transmucosal administration of drug compsns for treating and preventing disorders in animals
Velcera Pharmaceuticals; Novadel Pharma 1848270*

Treatment of topical use alleviating or inhibiting joint pain or muscle pain or musculoskeletal pain in a mammal
Scott, Donald 1848271*

18-membered macrocycles and analogues thereof
Optimer Pharmaceuticals 1848273*

Kappa opioid receptor ligands
Research Triangle Institute 1848275*

Tetrazine derivatives having an antimycotic effect, and use thereof
Phenion 1848276*

Oral formulations for delivery of catecholic butanes including NDGA compounds
Erimos Pharmaceuticals 1848278*

• Medical device for in situ liquid drug reconstitution in medicinal vessels
Medimop Medical Projects 1848393*

• Production of dosing moulds from active substance-containing melts
Abbott 1848394*

• Method for stimulating collagen synthesis and/or KGF expression
aTyr Pharma 1848395*

• Carboxylic acid containing dispersants for composites
Dentsply DeTrey 1848396*

• Compsn containing chitosan for sustained drug release
The Jordanian Pharmaceutical Manufacturing Co 1848397*

• Stabilisation of viral compsns
Aurx 1848398*

• Analgesic compsns
PharmaKodex 1848400*

• Silver-ionised plant extraction liquid and use thereof
Damyangkun 1848401*

• Rasagiline formulations of improved content uniformity
Teva Pharmaceutical Industries 1848402*

• Topical bioadhesive formulations
Camurus; Goddard, Christopher 1848403*

• Liquid carrier compsns with reduced polydispersity
Celator Pharmaceuticals 1848404*

• Atomchip device
Ben Gurion University of the Negev Research and Development Authority 1848405*

• Peroral, solid dosage form for contraception comprising dienogest and ethinylestradiol
Bayer Schering Pharma AG 1848406*

• Oral pharmaceutical compsn
Mega Lifesciences 1848407*

• Propanolol formulations
Alpharma 1848408*

• Propanolol formulations
Alpharma 1848409*

• Polymer particle delivery compsns and methods of use
Medivas 1848410*

• Copolyhydroxyalkylglutamines with are functionalised with hydrophobic groups and applications thereof, such as in therapeutics
Flamel Technologies 1848411*

• Transdermal systems having control delivery system
Mylan Technologies 1848412*

• Parenteral combination therapy for infective conditions with drug resistant bacterium
Venus Remedies 1848413*

• Method for treating gefitinib-resistant cancer
The General Hospital Corp; Wyeth 1848414*

• Combination therapy with glatiramer acetate and rasagiline for the treatment of multiple sclerosis
Teva Pharmaceutical Industries 1848415*

• Methods and materials with trans-clomiphene for the treatment of male infertility
Repros Therapeutics 1848416*

• Formulations of ladostigil tartrate
Teva Pharmaceutical Industries 1848417*

• Use of nordihydroguaiaretic acid derivatives in the treatment of drug resistant cancer, viral and microbial infection
Johns Hopkins University; Mold, David E; Lee, Yuan C; Chang, Chih-Chuan 1848418*

• Injectable preparations of diclofenic and its pharmaceutically acceptable salts
Troikaa Pharmaceuticals 1848419*

• Polymorphic forms of a GABAA agonist
Merck & Co 1848420*

• Natural remedy-dietary supplement combination product
Flavin-Koenig 1848421*

• Method for decreasing cartilage damage in dogs
Hill's Pet Nutrition 1848422*

• C10 cyclopropyl ester substituted taxane compsns
Florida State University Research Foundation 1848423*

• Pharmaceutical compsns comprising hydroxylated nebivolol
Mylan Laboratories 1848424*

• Therapeutic combinations of manidi pine and a statin
Chiesi Farmaceutici 1848425*

• Tricyclic cytoprotective compounds
Hunter-Fleming 1848426*

• Use of estrogen receptor-B selective agonists for radiation- or chemotherapy-induced mucosistis and radiation cystitis
Wyeth 1848427*

• Thiazole amides, imidazole amides and related analogues
Neurogen 1848428*

• Pharmaceutical agents containing fluoroalkylated metal complexes and epithilone
Bayer Schering Pharma 1848429*

• Novel benzylamine derivatives as CETP inhibitors
Reddy US Therapeutics; Baruah, Anima; De, Dibendyu; Khanna, Ish Kumar; Pillarisetti, Sivaram; Maitra, Santanu; Alexander, Christopher; Sreeny, Jennepalli; Dager, Indu 1848430*

• Liquid formulations for treatment of diseases or conditions
Macusight 1848431*

• Pharmaceutical compsns for the treatment or prevention of diseases involving obesity, diabetes, metabolic syndrome, neurodegenerative diseases and mitochondria dysfunction diseases
Md Bioalpha; KT & G  1848432*

• Methods and compsns using 4-amino-2-(3-methyl-2,6-dioxopiperidin-3-yl)-isoindole-1,3-dione
Celgene 1848433*

• A method for treating heart failure
Orion 1848434*

• Compounds for inflammation and immune-related issues
Synta Pharmaceuticals 1848435*

• Methods of diagnosis and treatment for asthma, allergic rhinitis and other respiratory diseases based on haplotype association
Decode Genetics EHF 1848436*

• Method for making pharmacokinetically improved compounds comprising functional residues or groups and pharmaceutical compsns comprising said compounds
Surface Logix; Lund, Frances; Duffy, David; Grogan, Michael; Kates, Steven; Ostuni, Emanuele; Schueller, Olivier; Sweetnam, Paul 1848437*

• Diaminophenothiazine compositions and uses thereof
Children's Hospital & Research Centre at Oakland 1848438*

• Oral immediate release formulation of a poorly water soluble substance
Solvay Pharmaceuticals; Panacea Biotec 1848439*

• Pharmaceutical compsn and method for regenerating myofibres in the treatment of muscle injuries
Lead Billion 1848440*

• Pharmaceutical compsn comprising drospirenone and ethynylestradiol
Laboratoires Liconsa 1848441*

• 2-methylene-19-nor-(20S-24epi)-1alpha, 25-dihydroxyvitamine-D2
Wisconsin Alumni Research Foundation 1848442*

• Compounds useful for treating HIV
Millennia Hope Pharmaceuticals 1848443*

• Processes for making lactose utilising pre-classification techniques and pharmaceutical formulations formed therefrom
Glaxo Group; Friesland Brands 1848444*

• Pharmaceutical compsns and method for neoangiogenesis/revascularisation useful in treating ischaemic heart diseases
Lead Billion 1848445*

• Use of iron (III) complex compounds
Vifor (International) 1848446*

• Biological tissue regenerative agent and method for preparing and using same
Gorrochategui Berrueta, Alberto; Barbera-Guillem, Emilio 1848447*

• Use of a lyophilised bacterial lysate for the prevention of tuberculosis relapse
IFB 1848448*

• Bioactive complex of triterpene acids, its production process and medicinal products with therapeutic uses
SC Biotehnos 1848449*

• A herbal mixture extract of pleurotus eryngii, acanthopancis cortex and notoginseng radix and a compsn comprising the same for prevention and treatment of periodontitis
Oscotec 1848450*

• Therapeutic uses of tomato extracts
Provexis Natural Products 1848451*

• Use of NKG2D receptor/NKG2D ligand interaction blockers in the treatment of auto-immune diseases
Eberhard-Karls-Universitaet Tuebingen 1848452*

• Treatment for neurodegeneration
Proximagen 1848453*

• Methods for treating lymphomas using a combination of chemotherapeutic agent and IL-2 and optionally an anti-CD20 antibody
Novartis Vaccines and Diagnostics 1848454*

• Use of calcitonin and calcitonin-like peptides to treat and prevent multiple sclerosis
Wisconsin Alumni Research Foundation 1848455*

• Poly-epitope peptide derived from thymidylate synthase having immunological and anti-tumour activity
Universita" Degli Studi di Siena 1848456*